Animal Models and Bevacizumab Testing
Author Information
Author(s): Eveno C, Gaujoux S, Tobelem G, Pocard M
Primary Institution: Unité Inserm U689, hôpital Lariboisière, Institut des Vaisseaux et du Sang, Paris, France
Hypothesis
Are animal models relevant for testing the efficacy of Bevacizumab?
Conclusion
Animal models may not accurately reflect the clinical efficacy of Bevacizumab due to differences in VEGF interaction.
Supporting Evidence
- Bevacizumab alone did not significantly inhibit tumor progression in the study.
- Human VEGF was more effectively inhibited by Bevacizumab compared to murine VEGF.
Takeaway
The study suggests that using animals to test a cancer drug might not work well because the drug doesn't interact the same way with animal proteins as it does with human ones.
Methodology
The study tested human endothelial cell proliferation in the presence of murine or human VEGF.
Potential Biases
Potential bias due to reliance on animal models that may not accurately represent human biology.
Limitations
The study does not provide specific limitations.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website